Abivax SA American is expected to report a Q2 2026 revenue consensus of $1.86 million and an EPS loss of $1.08, while its current stock price of $118.64 trades significantly below the analyst average price target of $156.38.
Investors are primarily focused on the upcoming New Drug Application (NDA) submission for lead candidate obefazimod in Ulcerative Colitis, currently slated for late 2026 following positive Phase 3 maintenance results and a favorable FDA interaction.
The company recently transformed its financial outlook by securing $920 million through a public offering in July 2026, which extended its cash runway into 2029. This capital surge provides critical support as Abivax advances its clinical pipeline toward commercialization milestones and continues Phase 2b trials for Crohn’s disease.